HGH Fragment 176-191
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic 16-amino-acid piece of growth hormone marketed for targeted fat loss without raising blood sugar or IGF-1. Nearly all supporting human data comes from a related peptide (AOD-9604), not this exact fragment, so real human evidence is thin and rests mostly on animal and mechanism studies. No published human safety trials exist for the unmodified peptide, and unregulated products sold online vary widely in quality. Not FDA-approved, and prohibited by WADA.
Read Full recordStudied uses & evidence
Studied uses(9)
Stimulates lipolysis (fat breakdown) in adipose tissue
MediumThe cited rodent, human-tissue, and clinical findings concern related fragments, including AOD-9401 and AOD-9604, rather than a human trial of unmodified hGH 176–191.
Inhibits lipogenesis (new fat formation)
LowShown in animal and ex vivo human tissue studies, but from one research group only.
Does not elevate IGF-1 levels
SpeculativeShown for the related compound AOD9604 in human trials, not directly tested for this fragment.
Evidence limits
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
ModerateFragment of GH with primarily lipolytic activity. Lower cancer risk than full GH but caution still warranted.
Diabetes/hypoglycemia risk
ModerateCan affect glucose metabolism. Monitor blood sugar when combined with antidiabetic agents.
General cautions
Pregnancy
AbsoluteNo reproductive safety data for this GH fragment.
Risk summary(12)
Risks = level of concern: High · Moderate · Low · Theoretical
No published human clinical trial safety data exists for the unmodified HGH Fragment 176-191 (all human data is for AOD-9604 derivative)
HighHigh-dose administration caused hyperglycemia and reduced insulin sensitivity in rats (Ng & Bornstein 1978)
ModerateFDA has cited immunogenicity (immune reaction) concerns for the closely related AOD-9604 peptide
ModerateFDA has cited concerns about peptide impurity profiles in compounded formulations of related peptides
ModerateLimited long-term safety data — longest AOD-9604 trial was 24 weeks; no data for unmodified fragment
ModerateQuality control variability in unregulated products sold online
HighPotential for degradation and loss of efficacy if improperly stored (peptide stability concerns)
LowInjection site reactions including redness, swelling, and irritation (reported anecdotally)
LowTransient headache reported anecdotally in user communities
LowProhibited by WADA — positive test could result in sanctions for competitive athletes
HighNo data on safety during pregnancy or lactation
ModerateExtrapolating AOD-9604 safety data to the unmodified fragment involves scientific uncertainty — the single amino acid difference could alter immunogenicity, stability, or pharmacokinetics
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.